NOTE: All in-article links open in a new tab.

January 2022 COVID-19 Updates

Published on 

Wednesday, January 26, 2022

January 5, 2022: CDC Expands Booster Shot Eligibility for 12-17 Year Old’s

The CDC announced in a newsroom release (link), they are endorsing the Advisory Committee on Immunization Practices’ (ACIP) recommendation to expand eligibility of booster doses to those 12 to 15 years old. They are also recommending that those 12 to 17 years old should receive a booster shot 5 months after their initial Pfizer-BioNTech vaccination series.

January 7, 2022: New HCPCS Code for Remdesivir Antiviral Medication

CMS issued a Special Edition MLN Connects (link) to let providers know they had created a HCPCS code J0248 for VEKLURY™ (remdesivir) antiviral medication when administered in the outpatient setting. This code is available for use by all payers and is effective for dates of service on or after December 23, 2021. They note that the MACs will determine Medicare coverage for HCPCS code J0248 administered in the outpatient setting and the MACs will be sharing coverage and claims processing information for this code.

December 31, 2021: CDC Health Advisory – Using Therapeutics to Prevent and Treat COVID-19
January 12, 2022: 2 New Procedure Codes Effective April 1, 2022

CMS published an ERRATA (link) to the ICD-10 MS-DRGs Version 39.1 effective April 1, 2022 to inform providers of “2 new procedure codes, in addition to the 7 new procedure codes previously announced, bringing the total to 9 new procedure codes, to describe the introduction of infusion or therapeutics, including vaccines for COVOID-19 treatment, into the” ICD-10-PCS. The 2 new codes are:

  • XW023X7: Introduction of tixagevimab and cilgavimab monoclonal antibody into muscle, percutaneous approach, new technology group 7, and
  • XW023Y7: Introduction of other new technology monoclonal antibody into muscle, percutaneous approach, new technology group 7.
January 13, 2022: COVID-19 Updates in CMS MLN Connects

The Thursday January 13th edition of MLN Connects (link) included information and resources about the following topics:

  • Updated Materials for Visiting Nursing Homes During Omicron Surge,
  • Vaccine Access in Long-Term Care Settings,
  • New HCPCS Code for Remdesivir Antiviral Medication – Updated NIH Treatment Guidelines Panel Link, and
  • Pfizer Booster Doses for Ages 12+ & Immunocompromised Ages 5-11.
January 14, 2022: Public Health Emergency Declaration due to COVID-19 Renewed

As expected, the COVID-19 Public Health Emergency was extended again on Friday, January 14th (link). This means waivers will remain in effect for 90 days (April 14, 2022).

April 2022 Update to the Medicare Severity-Diagnosis Related Group (MS-DRG) Grouper and Medicare Code Editor (MCE) Version 39.1 for ICD-10 Diagnosis Codes for 2019 COVID-19 Vaccination Status and ICD-10-PCS Codes for Introduction or Infusion of Therapeutics and Vaccines for COVID-19 Treatment
January 24, 2022: Free At-Home COVID-19 Tests

The CDC’s January 24th COVID-19 updates included a notice (link) that “every home in the United States is eligible to order 4 free at-home COVID-19 rapid antigen tests. Orders will usually ship in 7-12 days. These tests give results within 30 minutes (no lab drop-off required).” You can also go to https://www.covidtests.gov/ to order your tests.

Article Author: Beth Cobb, RN, BSN, ACM, CCDS
Beth Cobb, RN, BSN, ACM, CCDS, is the Manager of Clinical Analytics at Medical Management Plus, Inc. Beth has over twenty-five years of experience in healthcare including eleven years in Case Management at a large multi-facility health system. In her current position, Beth is a principle writer for MMP’s Wednesday@One weekly e-newsletter, an active member of our HIPAA Compliance Committee, MMP’s Education Department Program Director and co-developer of MMP’s proprietary Compliance Protection Assessment Tool.

This material was compiled to share information.  MMP, Inc. is not offering legal advice. Every reasonable effort has been taken to ensure the information is accurate and useful.